Filleted
Registration number:
Avicenna Herbal Products Ltd
for the Year Ended 31 March 2026
Avicenna Herbal Products Ltd
Contents
|
Company Information |
|
|
Balance Sheet |
|
|
Notes to the Unaudited Financial Statements |
Avicenna Herbal Products Ltd
Company Information
|
Director |
Youssef Izzat Nasr |
|
Registered office |
|
Avicenna Herbal Products Ltd
(Registration number: 10097099)
Balance Sheet as at 31 March 2026
|
Note |
2026 |
2025 |
|
|
Fixed assets |
|||
|
Tangible assets |
|
|
|
|
Current assets |
|||
|
Stocks |
|
|
|
|
Debtors |
|
|
|
|
Cash at bank and in hand |
|
|
|
|
|
|
||
|
Creditors: Amounts falling due within one year |
( |
( |
|
|
Net current assets |
|
|
|
|
Total assets less current liabilities |
|
|
|
|
Provisions for liabilities |
( |
( |
|
|
Net assets |
|
|
|
|
Capital and reserves |
|||
|
Called up share capital |
100 |
100 |
|
|
Retained earnings |
938,400 |
807,479 |
|
|
Shareholders' funds |
938,500 |
807,579 |
For the financial year ending 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
|
• |
|
|
• |
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts. |
Avicenna Herbal Products Ltd
(Registration number: 10097099)
Balance Sheet as at 31 March 2026
Approved and authorised by the
|
......................................... |
Avicenna Herbal Products Ltd
Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026
|
General information |
The company is a private company limited by share capital, incorporated in Wales.
The address of its registered office is:
These financial statements were authorised for issue by the
|
Accounting policies |
Summary of significant accounting policies and key accounting estimates
The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.
Statement of compliance
These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).
Basis of preparation
These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.
Tax
The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.
The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.
Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.
Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.
Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.
Avicenna Herbal Products Ltd
Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026
Tangible assets
Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.
Depreciation
Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:
|
Asset class |
Depreciation method and rate |
|
Property improvements |
10% reducing balance |
|
Fixtures and fittings |
20% reducing balance |
|
Plant and machinery |
20% reducing balance |
|
Office equipment |
20% reducing balance |
|
Motor vehicles |
20% reducing balance |
Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.
The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.
Dividends
Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.
|
Staff numbers |
The average number of persons employed by the company (including the director) during the year, was
Avicenna Herbal Products Ltd
Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026
|
Tangible assets |
|
Property Improvements |
Fixtures and fittings |
Plant and machinery |
Office equipment |
Motor vehicles |
Total |
|
|
Cost or valuation |
||||||
|
At 1 April 2025 |
|
|
|
|
|
|
|
Additions |
|
|
|
|
- |
|
|
At 31 March 2026 |
|
|
|
|
|
|
|
Depreciation |
||||||
|
At 1 April 2025 |
|
|
|
|
|
|
|
Charge for the year |
|
|
|
|
|
|
|
At 31 March 2026 |
|
|
|
|
|
|
|
Carrying amount |
||||||
|
At 31 March 2026 |
|
|
|
|
|
|
|
At 31 March 2025 |
|
|
|
|
|
|
Avicenna Herbal Products Ltd
Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026
|
Stocks |
|
2026 |
2025 |
|
|
Other inventories |
|
|
|
Debtors |
|
Current |
2026 |
2025 |
|
Trade debtors |
|
|
|
Prepayments |
|
|
|
Other debtors |
|
|
|
|
|
|
Creditors |
Creditors: amounts falling due within one year
|
Note |
2026 |
2025 |
|
|
Due within one year |
|||
|
Trade creditors |
|
|
|
|
Taxation and social security |
|
|
|
|
Other creditors |
4,524 |
4,524 |
|
|
|
|
Creditors: amounts falling due after more than one year
|
2026 |
2025 |
|
Share capital |
Allotted, called up and fully paid shares
|
2026 |
2025 |
|||
|
No. |
£ |
No. |
£ |
|
|
|
|
100 |
|
100 |
Avicenna Herbal Products Ltd
Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026
|
Related party transactions |
|
Transactions with the director |
|
2026 |
At 1 April 2025 |
Advances to director |
Repayments by director |
At 31 March 2026 |
|
Youssef Izzat Nasr |
||||
|
Interest charged at HMRC's official rate on balances >£10,000 |
|
|
( |
|
|
2025 |
At 1 April 2024 |
Advances to director |
Repayments by director |
At 31 March 2025 |
|
Youssef Izzat Nasr |
||||
|
Interest charged at HMRC's official rate on balances >£10,000 |
- |
|
( |
|